Ascent Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Ascent Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$434K	Sell	3,395 -488	-13%	-$60.9K	0.02%	530
2025 Q4	$473K	Buy	+3,883	New	+$445K	0.02%	507
2024 Q4	–	Sell	-7,935	Closed	-$784K	–	556
2024 Q3	$784K	Buy	+7,935	New	+$780K	0.06%	316
2022 Q2	–	Sell	-23,536	Closed	-$2.12M	–	510
2022 Q1	$2.12M	Buy	+23,536	New	+$2.17M	0.25%	142

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ascent Group's XBI Position: Q1 2026 in Review

Ascent Group reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 13% in Q1 2026, selling an estimated $60.9K and leaving 3,395 shares worth $434K. The position accounts for 0.02% of the portfolio, ranked #530.

Ascent Group first reported a position in XBI in Q1 2022 and has held it in 4 quarters since. The position peaked at $2.12M in Q1 2022. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Ascent Group held 3,395 shares of State Street SPDR S&P Biotech ETF worth $434K as of Q1 2026.
Ascent Group sold 488 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $60.9K.
State Street SPDR S&P Biotech ETF made up 0.02% of Ascent Group's portfolio in Q1 2026, its #530 holding.
Ascent Group first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and has held it in 4 quarters since.
Ascent Group's State Street SPDR S&P Biotech ETF position peaked at $2.12M in Q1 2022.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Ascent Group's 13F filing for Q1 2026, filed 15 May 2026.